TPOXX

TPOXX is the brand name for tecovirimat, an antiviral medication developed to treat infections caused by orthopoxviruses, including variola (smallpox) and mpox (monkeypox). It was first approved in the United States for the treatment of smallpox in adults and pediatric patients and has since been used under expanded access and regulatory approvals in other countries for mpox outbreaks. The product label covers treatment of orthopoxvirus infections in adult and pediatric patients weighing at least 13 kilograms, with dosing and duration defined by regulatory guidance.

Mechanism of action: Tecovirimat targets the p37 viral envelope protein, which is essential for the formation of extracellular enveloped virions. By inhibiting this protein, the drug limits the spread of the virus within the host and helps contain infection.

Medical use: The medicine is indicated for orthopoxvirus infections, including mpox, in adults and children. It is typically prescribed when antiviral therapy is indicated and is used as part of clinical management under regulatory authorization. Dosing is weight-based and usually given for a defined course, commonly around 14 days, with specifics provided in official labeling.

Administration and pharmacokinetics: Tecovirimat is administered orally as capsules, with dosing tailored to patient weight and age according to regulatory labeling. The availability of formulations and routes may vary by country, and healthcare providers consult official guidelines for detailed administration instructions.

Safety and adverse effects: Tecovirimat is generally well tolerated. Reported adverse events include headaches, nausea, abdominal pain, and vomiting, with rare serious events. Safety data in pregnancy and in special populations are limited, and treatment decisions should weigh potential benefits against risks as described in the product labeling.

Regulatory status: TPOXX has received regulatory approvals or authorizations in multiple jurisdictions for smallpox and mpox treatment, along with guidance and access programs managed by national health authorities.